Subscribe To
RYZB / RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RYZB News
By Seeking Alpha
October 10, 2023
RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re more_horizontal
By Market Watch
September 15, 2023
RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion
Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% abo more_horizontal
By Proactive Investors
September 15, 2023
RayzeBio to go public at $1B market valuation
RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offeri more_horizontal
By Market Watch
September 15, 2023
RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offer more_horizontal
By Market Watch
September 11, 2023
RayzeBio sets IPO terms, to be valued at up to $1 billion
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Pha more_horizontal